OKYO PHARMA LIMITED

Epic: OKYO

MARKET: Main Market

WEBSITE: https://www.okyopharma.com/

All data delayed by at least 15 minutes.

* All information stated is correct at time of publishing and may be subject to change without notice.

Who are Okyo Pharma

OKYO Pharma Limited (LSE:OKYO, OCTQB:EMMLF) is a biopharmaceutical company developing next-generation therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. Our goal is to develop first in class drug candidates that prevent the disease instead of controlling it, and we achieve this through our collaboration with pioneer scientists in the field.

MEET THE TEAM

Willy Simon

Executive Chairman

Dr. Kunwar Shailubhai M.B.A.

Non-executive Director

John Brancaccio

Non-Executive Director

Pello Capital do not accept any liability arising from any inaccurancy or omission in the information on the OKYO website.
We advise you to verify the accurancy of any information before relying on it.

Latest News

LOG IN   OR   Sign Up   to accept and place an order



Alternatively, get in touch on 0203 700 2500 or email hello@pellocapital.com

Have your say….

Do you want to know more about Okyo Pharma

Do you want to stay connected with the company?

Do you just want to have your say…..

Pello Spotlight will relay your comments back to Okyo Pharma and give you the

chance to stay connected.

Cornhill Capital Limited offers investments and services to clients, which are primarily considered to be high risk investments. Some investments such as contracts for difference use leverage which can magnify gains but equally can magnify losses. Leveraged products may lose investors more than the amount they initially invested. This website is provided for information purposes only. It is not an offer to sell, or a solicitation of an offer to buy, any security, nor enter into any agreement or contract with Cornhill Capital Limited. All information provided is indicative and subject to market conditions and availability. Not all financial products are suitable for all investors. Before entering into any transaction you should ensure that you understand and have made an independent assessment of the suitability and appropriateness of the transaction into which you are entering and the nature and extent of your exposure to risk of loss in light of your own objectives, financial and operational resources and other relevant circumstances. You should take such independent investigations and such professional advice as you consider necessary or appropriate for such purpose. Past performance is no indicator of future success.